Phenobarbital Market Key Players Analysis - Sanofi, Pfizer Inc., Novartis AG, Teva Pharmaceutical Industries Ltd., Mylan N.V., Sun Pharmaceutical Industries Ltd.

InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Phenobarbital Market- (By Indication (Epilepsy, Neonatal seizures), By Dosage Form (Tablets, Injectable, Formulations), By Distribution channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031."

According to the latest research by InsightAce Analytic, the Global Phenobarbital Market is valued at US$ 1.48 Bn in 2022, and it is expected to reach US$ 2.20 Bn by 2031, with a CAGR of 4.6% during a forecast period of 2023-2031.

Get Free Access to Demo Report, Excel Pivot and ToC: https://www.insightaceanalytic.com/request-sample/2049

The sedative and anti-seizure effects of phenobarbital, a class C-IV control drug, are used to treat alcohol withdrawal in individuals with status epilepticus. A barbiturate drug, phenobarbital, is also referred to as phenobarbitone or phenobarb and is available under the brand names Luminal and other names. The World Health Organisation (WHO) recommends it for the management of specific forms of epilepsy in underdeveloped nations. Phenobarbital is only administered intravenously in dire circumstances.

According to studies, induration at the infusion site reduces the bioavailability of phenobarbital. It is advised to taper off the medicine because abrupt stopping can cause withdrawal symptoms in patients. According to the American Epilepsy Society's most recent recommendations, phenobarbital is often administered intravenously (15 mg/kg) to adult patients with status epilepticus. Phenobarbital has a long history of usage and is well-known for its effectiveness in the treatment of epilepsy and seizure disorders. It is regarded as a first-line treatment for several types of seizures, especially in areas with limited resources. Due to the medication's success in reducing seizures, there is a demand for it on the market.

List of Prominent Players in the Phenobarbital Market:
• Sanofi
• Pfizer Inc.
• Novartis AG
• Teva Pharmaceutical Industries Ltd.
• Mylan N.V.
• Sun Pharmaceutical Industries Ltd.
• Hikma Pharmaceuticals
• Zydus Cadila
• Lannett Company, Inc.
• Strides Pharma Science Limited
• Cipla Ltd.
• Lupin Limited
• Aurobindo Pharma Limited
• Torrent Pharmaceuticals Ltd.
• Reddy's Laboratories Ltd.

Expert Knowledge, Just a Click Away: https://calendly.com/insightaceanalytic/30min?month=2024-02

Market Dynamics:
Drivers-
An established manufacturing, distribution, and prescription infrastructure supports the accessibility of phenobarbital. Patients who require anticonvulsant therapy can easily acquire the medication because of this infrastructure, which guarantees a steady supply to hospitals and pharmacies. The market for phenobarbital is significantly driven by the prevalence of epilepsy and seizure disorders. Bns of individuals around the world suffer from epilepsy, and there is a continuing need for potent anticonvulsants. With its well-established efficacy, phenobarbital is essential in treating epilepsy, particularly in areas where the condition is more common.

Challenges:
The drug phenobarbital has a number of undesirable side effects, such as drowsiness, cognitive decline, vertigo, and behavioural abnormalities. These side effects, particularly when the medicine impairs everyday activities or cognitive function, may affect patient compliance and quality of life. Safety considerations regarding the possibility of extreme adverse events, such as infrequent but severe adverse reactions, must also be taken into account.

Regional Trends:
The North American phenobarbital market is expected to register a major market revenue share and it is projected to grow at a high CAGR in the near future. The emergence of new market participants and advancement of the paediatric formulation is anticipated to drive the market expansion in the coming years. Moreover, increasing research and development efforts aimed at improving the phenobarbital formulation's effectiveness, safety, and efficacy are the factors responsible for the market's development during the forecast period. The increasing trend of personalized treatment approaches in the country is expected to boost the market growth.

Unlock Your GTM Strategy: https://www.insightaceanalytic.com/customisation/2049

Recent Developments:
• In May 2023, Mallinckrodt, Inc. introduced a new generic variety of phenobarbital pills. The medication is offered in strengths of 15 mg, 30 mg, and 60 mg, and the majority of significant insurance policies cover it.
• In January 2023, Sun Pharma launched a brand-new, extended-release phenobarbital medication. Sun Pharma Introduces SEZABYTM (phenobarbital Sodium) for the Treatment of Neonatal Seizures in the United States.

Segmentation of Phenobarbital Market-
By Indication-
• Epilepsy
• Neonatal seizures
By Dosage Form-
• Tablets
• Injectable
• Formulations
By Distribution channel-
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
By Region-
North America-
• The US
• Canada
• Mexico
Europe-
• Germany
• The UK
• France
• Italy
• Spain
• Rest of Europe
Asia-Pacific-
• China
• Japan
• India
• South Korea
• South East Asia
• Rest of Asia Pacific
Latin America-
• Brazil
• Argentina
• Rest of Latin America
Middle East & Africa-
• GCC Countries
• South Africa
• Rest of Middle East and Africa

Empower Your Decision-Making with 180 Pages Full Report @ https://www.insightaceanalytic.com/buy-report/2049

About Us:
InsightAce Analytic is a market research and consulting firm that enables clients to make strategic decisions. Our qualitative and quantitative market intelligence solutions inform the need for market and competitive intelligence to expand businesses. We help clients gain competitive advantage by identifying untapped markets, exploring new and competing technologies, segmenting potential markets and repositioning products. Our expertise is in providing syndicated and custom market intelligence reports with an in-depth analysis with key market insights in a timely and cost-effective manner.

Contact us:
InsightAce Analytic Pvt. Ltd.
Visit: www.insightaceanalytic.com
Tel : +1 551 226 6109
Asia: +91 79 72967118
info@insightaceanalytic.com

This release was published on openPR.